> Community > Life Sciences members > Cellestia Biotech

Cellestia Biotech

Cellestia is giving hope to cancer patients who have no other treatment or therapy options by developing innovative targeted therapies. Our drug discovery platform is built on a unique mode of action of targeting protein-protein interactions (PPI) with small molecules. Together with companion diagnostics, Cellestia provides a first-in-class solution by targeting oncogenic transcription factors. Our clinical candidate drug CB-103 is targeting orphan cancers such as cancer of the salivary gland (adenoid cystic carcinoma) and a subtype of childhood leukaemia. At the same time, we are continuing to expand our portfolio through (i) targeting large cancer indications with CB-103, such as breast cancer, and (ii) developing novel PPI inhibitors for additionnal oncology indications. Cellestia is a privately-owned clinical-stage biopharma company (phase I) led by an experienced team of scientists, drug developers and business professionals.

Research description

  • In-house research to support clinical development of lead candidate in oncology and non-oncology indication.
  • Targeting novel “undruggable” transcription factors.
  • Support pipeline expansion based on in-house research.

Cellestia Biotech
STARTLAB
Alanine Building
Route de la Corniche 5
1066 Epalinges

Keywords

  • Oncology
  • Precision Medicine
  • Undruggable transcription factors